OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 435,430 shares, a drop of 12.4% from the February 12th total of 497,204 shares. Based on an average daily trading volume, of 305,091 shares, the short-interest ratio is presently 1.4 days. Currently, 1.8% of the company’s stock are sold short. Currently, 1.8% of the company’s stock are sold short. Based on an average daily trading volume, of 305,091 shares, the short-interest ratio is presently 1.4 days.

Hedge Funds Weigh In On OKYO Pharma

A number of institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new stake in OKYO Pharma during the 3rd quarter valued at approximately $31,000. Renaissance Technologies LLC increased its stake in shares of OKYO Pharma by 235.0% in the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after acquiring an additional 96,800 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of OKYO Pharma during the fourth quarter worth $36,000. 2.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on OKYO shares. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of OKYO Pharma in a research note on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research note on Thursday, January 22nd. B. Riley Financial began coverage on shares of OKYO Pharma in a report on Monday, December 8th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, Piper Sandler assumed coverage on OKYO Pharma in a report on Friday, February 20th. They set an “overweight” rating and a $7.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $6.33.

OKYO Pharma Trading Up 1.2%

OKYO Pharma stock opened at $1.68 on Tuesday. The business’s 50-day simple moving average is $2.01 and its two-hundred day simple moving average is $2.11. OKYO Pharma has a fifty-two week low of $1.03 and a fifty-two week high of $3.35.

OKYO Pharma (NASDAQ:OKYO) last announced its quarterly earnings data on Friday, January 30th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($2.21). As a group, analysts expect that OKYO Pharma will post -0.17 earnings per share for the current fiscal year.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.